What changed in 2026, by region

What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked.

Documenting an access outcome, dated, because everything in this category expires.

As of April 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

Taking post #9 at face value and following it one step further.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

This is where my knowledge stops and I would rather mark the edge than blur it.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

If this contradicts something upthread, the upthread version may well be the better one.

Confirming post #70 from a second method, which matters more than confirming it from a second person.

A first-hand dated account for a region with thin coverage is worth more here than any summary, and the regions with thin coverage are most of them.

Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.

Speaking for myself and not for anyone else who has posted here.

Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.

It is worth stating the boring hypothesis before the interesting one.

This follows post #105 rather than contradicting it.

Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

Adding a source would improve this post and I do not have one to hand.